Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications

Antimetabolites, Antineoplastic/*therapeutic use ; Azacitidine/*therapeutic use ; Leukemia, Myeloid, Acute/*drug therapy ; Myelodysplastic Syndromes/*drug therapy; Abnormal Karyotype ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Azacitidine/administration & dosage ; Azacitidine/adverse effects ; Bone Marrow Diseases/chemically induced ; Disease Progression ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Febrile Neutropenia/chemically induced ; Female ; France/epidemiology ; Hospitalization/statistics & numerical data ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/mortality ; Male ; Multicenter Studies as Topic ; Myelodysplastic Syndromes/mortality ; Renal Insufficiency, Chronic/epidemiology ; Retrospective Studies ; Treatment Outcome

Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32:2541-52.
Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536-42.
Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010;85:130-8.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291-9.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-32.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-405.
Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, et al. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol. 2014;89:410-6.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130:1514-22.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, et al. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): a prospective single-arm phase 2 trial. Cancer Sci. 2018;109:3209-15.

0 (Antimetabolites, Antineoplastic)
M801H13NRU (Azacitidine)

Date Created: 20200513 Date Completed: 20210303 Latest Revision: 20210303

20240829

10.1111/bjh.16680

32394477